Jackson Center, PA, September 8, 2021 – Halberd Corporation (OTC PINK:HALB) announced the appointment of Anthony Mirabelli to the position of Vice-President, Mergers & Acquisitions. Mirabelli will be responsible for negotiating joint ventures, license agreements and other activities whereby Halberd can capitalize on his vast experience in pharmaceutical and medical device development and sales. Anthony ...
Jackson Center, PA, August 25, 2021 – Halberd Corporation (OTC-PINK: "HALB") received notification from the Ference Law Firm in Pittsburgh of a Notice of Allowance, by the US Patent Office, for the treatment of Cockayne Syndrome. Cockayne Syndrome is a fatal autosomal recessive neurodegenerative disorder which causes premature aging and severely impaired development of the ...
Jackson Center, PA, August 23, 2021 – Halberd Corp. (OTC PINK: "HALB") announced filing a U. S. joint provisional patent application, “Treating Alzheimer’s Disease Utilizing Extracorporeal Radio Frequency.” The innovation is a result of Halberd’s Sponsored Research conducted at Arizona State University (ASU) and Youngstown State University (YSU). The provisional patent application covers technology developed ...
Jackson Center, PA, July 22, 2021 – Halberd Corporation (OTC-PINK: "HALB") confirms the shipment of samples of metallic nanoparticles conjugated to Alzheimer’s Disease (AD) antibodies, Tau and Phosphorylated Tau. Having successfully conjugated the metallic nanoparticles (via its breakthrough patent-pending process), GreenBioAZ shipped the materials to Youngstown State University (YSU). At YSU, Dr. William G. Sturrus, ...
Method Does Not Require Antibody Conjugated Metallic Nanoparticles Jackson Center, PA, June 30, 2021 – Halberd Corporation (OTC-PINK: "HALB") announces a possible breakthrough method for the removal of the disease-causing antigen(s) that does not require the use of metallic nanoparticles conjugated to antibodies. This simplified method for the removal of disease-causing antigen(s) utilizes more conventional ...
Jackson Center, PA, June 21, 2021 – Halberd Corporation’s (OTC-PINK: "HALB") proprietary technology enters stage 4 to address Alzheimer’s Disease (and other potential diseases); eradicating the antibody-disease combination through radiofrequency waves or laser or other means. Currently, there is no known effective treatment for Alzheimer’s Disease which afflicts over 40 million people worldwide, equivalent to ...
Enables Extracorporeal Eradication of Pathogens from Cerebral Spinal Fluid Via Radio Frequency and/or Laser Emissive Energy Jackson Center, PA, June 16, 2021 – Halberd Corporation (OTC-PINK: "HALB") has successfully conjugated, Tau, Phosphorylated Tau and Beta Amyloid antibodies with gold-coated iron oxide nanoparticles in a patent-pending process. These three antigens, which are found in Cerebral Spinal ...
Jackson Center, PA, June 9, 2021 – Halberd Corporation (OTC-PINK: "HALB") commences experimentations to eradicate three of the principal components of Alzheimer’s Disease. By eliminating these three critical antigens, which form the basis for neurofibrillary tangles in the brain, Halberd believes that its patented extracorporeal treatment process can slow or stop the progress of the ...
Breakthrough Achievement Enables Extracorporeal Eradication of Pathogens Via Radio Frequency Waves and/or Laser Emissive Energy Jackson Center, PA, May 25, 2021 – Halberd Corporation (OTC-PINK: "HALB") announces the successful conjugation of gold-coated iron nanoparticles with an available E.coli antibody. This milestone is a result of the Halberd sponsored research being conducted at GreenBioAz by Dr. ...
Jackson Center, PA, May 19, 2021 – Halberd Corporation (OTC-PINK: "HALB") was featured in a recent MarketWatch article, “New Approaches to Covid-19 Treatment Enter the Picture,” along with six other notable biotechnology companies. As stated in the article, “The Covid-19 treatment response process includes a number of different major players, including Pfizer Inc (NYSE:PFE), BioNTech ...